If we we look at the therapies described for the last five years, the rituximab-bendamustine combination is one of that novel options. And then we have the complement-directed therapies, which are highly novel options. And of course they will be expanded in the future, certainly. Well, now we have good documentation for the effect of temelimab. It’s a highly promising option and we know much about the favorable effect and the lack of toxicity...
If we we look at the therapies described for the last five years, the rituximab-bendamustine combination is one of that novel options. And then we have the complement-directed therapies, which are highly novel options. And of course they will be expanded in the future, certainly. Well, now we have good documentation for the effect of temelimab. It’s a highly promising option and we know much about the favorable effect and the lack of toxicity. But there will be more options during the first two years to come. For example, C3 inhibition with pegcetacoplan. We have not the Phase III studies yet, but I’m sure that they will come. Also, another option that I have not mentioned is the newer, more specific B-cell-directed therapies, like for example, ibrutinib or other Bruton’s tyrosine kinase inhibitors. There is a very promising retrospective study of ibrutinib and I think further studies of the tyrosine kinase inhibitors should come.